07:59 AM EDT, 10/28/2024 (MT Newswires) -- Evoke Pharma ( EVOK ) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.

The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.

It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.

Shares of the drug developer more than doubled in premarket activity.

Price: 11.50, Change: +6.37, Percent Change: +124.17